At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
GR-MD-02drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Open-Label Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Patients With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating GR-MD-02 for Psoriasis. Completed, enrolled 5 participants across 1 site.
Detailed Summary
Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to severe plaque psoriasis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartSep 2015
Primary CompletionMar 2018
TodayJul 2026
First PostedApr 2, 2015
Enrollment StartSep 1, 2015
Primary CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.3 years ago
Interventions
GR-MD-02drug
IV infusion